Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Hip fracture is both a cause and a consequence of sarcopenia. Older persons with sarcopenia have an increased risk of falling, and the prevalence of sarcopenia may be increased in those who suffer a hip fracture. The aim of this study was to explore potential biomarkers (neuromuscular and peripheral pro‐inflammatory and oxidative stress markers) that may be associated with sarcopenia in very old persons with hip fracture.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We recruited 150 consecutive patients ≥80 years old admitted to an orthogeriatric unit for an osteoporotic hip fracture. Muscle mass was assessed pre‐operatively using bioelectrical impedance analysis; Janssen's (J) and Masanés' (M) reference cut‐off points were used to define low muscle mass. Muscle strength was assessed with handgrip strength (Jamar's dynamometer). Sarcopenia was defined by having both low muscle mass and strength and using the European Working Group on Sarcopenia in Older People 2 definition of probable sarcopenia (low grip strength). Peripheral markers—pro‐inflammatory and oxidative stress parameters—were determined either in the plasma or in the erythrocyte fraction obtained from peripheral whole blood of every patient pre‐operatively.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Mean age was 87.6 ± 4.9 years, and 78.7% were women. The prevalence of sarcopenia was 11.5% with Janssen's, 34.9% with Masanés' cut‐offs, and 93.3% with the European Working Group on Sarcopenia in Older People 2 definition of probable sarcopenia. Among the four pro‐inflammatory cytokines tested in plasma, only tumour necrosis factor‐α was different (lower) in sarcopenic than in non‐sarcopenic participants using both muscle mass cut‐offs (J 7.9 ± 6.2 vs. 8.3 ± 5.8, M 6.8 ± 4.7 vs. 9.1 ± 6.2). Erythrocyte glutathione system showed a non‐significant tendency to lower glutathione levels and glutathione/oxidized glutathione ratios in sarcopenic participants compared with non‐sarcopenic subjects. Catalase activity was also lower in sarcopenic participants (J 2904 ± 1429 vs. 3329 ± 1483, M 3037 ± 1430 vs. 3431 ± 1498). No significant differences were found between groups in chymotrypsin‐like activity of the 20S proteasome, superoxide dismutase, glutathione peroxidase and butyrylcholinesterase activity, C‐terminal agrin fragment, interferon‐γ, or interleukin‐1β.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The prevalence of sarcopenia in patients with hip fracture varies according to the definition and the muscle mass reference cut‐off points used. We did not find differences in most neuromuscular, pro‐inflammatory, or oxidative stress markers, except for lower peripheral tumour necrosis factor‐α levels and catalase activity in sarcopenic participants, which may be markers of an early inflammatory reaction that is hampered in sarcopenic patients.</p></section>

The relationship between growth hormone kinetics and sarcopenia in postmenopausal women: the role of fat mass and leptin.

Associations Between Elevated Growth Differentiation Factor-15 and Sarcopenia Among Community-dwelling Older Adults

Evaluation of Sarcopenia in Elderly Women of China

A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study

Independent association between serum C-peptide levels and fat mass-to-lean mass ratio in the aging process.

Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study

Factors associated with muscle mass

Role of the Cytokine-like Hormone Leptin in Muscle-bone Crosstalk with Aging

Age-Dependent Decline in Acyl-Ghrelin Concentrations and Reduced Association of Acyl-Ghrelin and Growth Hormone in Healthy Older Adults

Serum concentrations of insulin-like growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women

The impact of sarcopenic obesity on inflammation, lean body mass, and muscle strength in elderly women

Growth Hormone and Aging: New Findings

Prevalence and Factors Associated with Sarcopenia in Post-Menopausal Women with Rheumatoid Arthritis

Epigenome-wide association study of sarcopenia: findings from the Hertfordshire Sarcopenia Study (HSS)

Age-Related Changes in Insulin Resistance and Muscle Mass: Clinical Implications in Obese Older Adults

Biomarkers of sarcopenia in very old patients with hip fracture

Reduced energy metabolism contributing to aging of skeletal muscle by serum metabolomics and gut microbiota analysis

On the Definition of Sarcopenia in the Presence of Aging and Obesity—Initial Results from UK Biobank

Associations Between Female Sex Hormones and Skeletal Muscle Ageing: The Baltimore Longitudinal Study of Aging

Skeletal muscle myostatin gene expression and sarcopenia in overweight and obese middle-aged and older adults

Metabolic signatures and risk of sarcopenia in suburb-dwelling older individuals by LC-MS–based untargeted metabonomics